Perspective: Determinants of the severity of poliovirus outbreaks in the post eradication era

Risk Analysis

Volumn 26, Issue 6, 2006, Pages 1533-1540

  Fine, P E M ^a   Ritchie, S ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH RISKS; PATIENT TREATMENT; PUBLIC POLICY; SANITATION; VACCINES; VIRUSES;

OPV CESSATION; POLIOVIRUS OUTBREAKS; POLIOVIRUS TRANSMISSION; SELF-LIMITED TRANSMISSION;

DISEASES;

ORAL POLIOMYELITIS VACCINE;

DISEASE TRANSMISSION; HEALTH POLICY; POLIOMYELITIS; VACCINATION; VIRUS;

DISEASE SEVERITY; DRUG EFFICACY; ECONOMIC ASPECT; ENVIRONMENTAL SANITATION; EPIDEMIC; ERADICATION THERAPY; HEALTH CARE POLICY; HUMAN; INFECTION RISK; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLITICS; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

DISEASE OUTBREAKS; DISEASE TRANSMISSION; HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; PUBLIC HEALTH; RISK ASSESSMENT; VIRULENCE; WORLD HEALTH;

POLIOVIRUS;

EID: 33845656557     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2006.00855.x     Document Type: Review

References (26)

1. WHO. (2003). Global Polio Eradication Initiative: Strategic plan 2004-2008. Geneva: WHO.
2. Henderson, D. A. (2002). Countering the posteradication threat of smallpox and polio. Clin Inf Dis, 34, 79-83.
3. LagoMas, P., Ramon Bravo, J., Andrus, J. K. et al. (1994). Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull WHO, 72, 221-225.
4. DuintjerTebbens, R. J., Pallansch, M. A., Kew, O. M., Caceras, V. M., Jafari, H., Cochi, S. L., Sutter, R. W., Aylward, R. B., & Thompson, K. M. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 26(6), 1471-1505.
5. Fine, P. E. M., Sutter, R. W., & Orenstein, W. A. (2001). Stopping a polio outbreak in the post-eradication era. Developments in Biologicals Progress in polio eradication: vaccine strategies for the end game, 105, 129-147.
6. Sutter, R. W., Caceras, V. M., & Mas Lago, P. (2004). The role of routine polio immunization in the post-certification era. Bull WHO, 82, 31-9.
7. DuintjerTebbens, R. J., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Sutter, R. W., & Thompson, K. M. (2005). A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 162(4), 358-372.
8. Fine, P. E. M., Oblapenko, G., & Sutter, R. W. (2004). Polio control after certification: major issues outstanding. Bull WHO, 82, 47-52.
9. Fine, P. E. M., & Carneiro, I. A. M. (1998). Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative. Unpublished document prepared for WHO Polio Programme. May, 85 pp.
10. Fine, P. E. M., & Carneiro, I. A. M. (1999). Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initative. Am J Epidemiol, 150, 1001-1021.
11. Kew, O. M., Sutter, R. W., de Gourville, E., Dowdle, W., & Pallansch, M. (2005). Vaccine-derived Polioviruses and the endgame strategy for global polio eradiction. Annu Rev Microbiol, 59, 587-635.
12. Centers for Disease Control and Prevention. (2005). Poliovirus infections in four unvaccinated children - Minnesota, August-October 2005. Morbidity and Mortality Weekly Report, 54, 1053-5.
13. Thompson, K. M., Tebbens, R. J. D., & Pallansch, M. A. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis, 26(6), 1541-1556.
14. th Edition, Saunders/Elsevier: pp 651-705.
15. Kohler, K. A., Banerjee, K., Gary Hlady, W., Andrus, J. K., & Sutter, R. W. (2002). Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Org., 80, 210-6.
16. Dowdle, W. R., Van der Avoort, H., de Gouville, E., Delpeyroux, F., Desphande, J., Hovi, T., Martin, J., Pallansch, M., Kew, O., & Wolff, C. Containment of polioviruses after eradication and OPV cessation: Characterizing risks to improve management. Risk Analysis, 26(6), 1449-1469.
17. Eichner, M., Hadeler, K. P., & Dietz, K. (1996). Stochastic models for the eradication of poliomyelitis: minimum population size for poliovirus persistence. In Models for Infectious Human Diseases: Their Structure and Relation to Data. Isham V. and Medley G. eds. Cambridge: Cambridge University Press.
18. Hufnagel, L., Brickman, D., & Geisel, T. (2004). Forecast and control of epidemics in a globalised world. Proc Natl Acad Sci USA, 101, 15124-15129.
19. Melnick, J. L. (1959). Studies on the serological epidemiology of poliomyelitis as an index in certain Caribbean Islands, British Guiana, and Ecuador. West Ind Med J, 8, 275-298.
20. Centers for Disease Control and Prevention. (2006). Resurgence of wild poliovirus type 1 transmission and consequences of importation - 21 countries, 2002-2005. Morbidity and Mortality Weekly Report, 55, 145-50.
21. Kojouharova, M., Zuber, P. L. F., Gyurova, S., Fiore, L., Butinelli, G., Kunchev, A., Vladimirova, N., Korsun, N., Filipova, R., Boneva, R., Gavrilin, E., Deshpande, J. M., Oblapenko, G., & Wassilak, S. G. (2003). Importation and circulation of poliovirus in Bulgaria in 2001. Bull WHO, 81, 476-481.
22. John, T. J. (2004). A developing country perspective on vaccine-associated paralytic poliomyelitis. Bull WHO, 82, 53-8.
23. th Edition, Saunders / Elsevier: pp 625-649.
24. John, T. J. (2004). 'Polar spectrum' of problems in polio eradication. Ind J Med Res, 120, 133-135.
25. Eichner, M., & Dietz, K. (1996). Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol, 143, 816-822.
26. WHO. (2006). Inactivated poliovirus vaccine (IPV) following oral poliovirus cessation. Weekly Epidemiol Rec (in press).